Rigel Pharmaceuticals, Inc. (RIGL)
NASDAQ: RIGL · Real-Time Price · USD
30.56
+0.05 (0.16%)
At close: Apr 28, 2026, 4:00 PM EDT
30.56
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:48 PM EDT
Rigel Pharmaceuticals Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Rigel Pharmaceuticals stock have an average target of 45.67, with a low estimate of 38 and a high estimate of 57. The average target predicts an increase of 49.44% from the current stock price of 30.56.
Analyst Consensus: Strong Buy
* Price targets were last updated on Nov 5, 2025.
Analyst Ratings
The average analyst rating for Rigel Pharmaceuticals stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 3 | 3 | 3 | 3 | 3 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 6 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Hold → Strong Buy Upgrades $23 → $42 | Hold → Strong Buy | Upgrades | $23 → $42 | +37.43% | Nov 5, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Hold Maintains $32 → $38 | Hold | Maintains | $32 → $38 | +24.35% | Nov 5, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $57 | Strong Buy | Reiterates | $57 | +86.52% | Oct 8, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Hold Maintains $23 → $32 | Hold | Maintains | $23 → $32 | +4.71% | Aug 6, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Hold Maintains $20 → $23 | Hold | Maintains | $20 → $23 | -24.74% | May 7, 2025 |
Financial Forecast
Revenue This Year
289.81M
from 294.28M
Decreased by -1.52%
Revenue Next Year
326.75M
from 289.81M
Increased by 12.75%
EPS This Year
4.21
from 19.48
Decreased by -78.39%
EPS Next Year
3.75
from 4.21
Decreased by -10.99%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 301.7M | 372.0M | ||||||
| Avg | 289.8M | 326.8M | ||||||
| Low | 274.9M | 300.7M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 2.5% | 28.4% | ||||||
| Avg | -1.5% | 12.7% | ||||||
| Low | -6.6% | 3.8% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 4.97 | 4.12 | ||||||
| Avg | 4.21 | 3.75 | ||||||
| Low | 3.55 | 3.42 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -74.5% | -2.2% | ||||||
| Avg | -78.4% | -11.0% | ||||||
| Low | -81.8% | -18.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.